The results of a new School of Medicine study could eventually have oncologists removing their specialties from their shingles by making therapy based on a tumor’s anatomical location obsolete.
When the study’s researchers compared eight different kinds of cancerous tumors, they saw that whether the tumor was, for instance, a breast tumor, lung tumor or colon tumor didn’t correlate to how the cancers interacted with a standard anticancer drug.
Their findings suggest that traditional cancer treatments — which have established different drug regimens for brain, prostate or ovarian cancer, for example — should eventually be replaced with therapies that use drugs deemed to be of highest benefit based on the tumor’s pharmacologic profile. Treatment choice would be determined by how each patient’s tumor reacts to anticancer drugs, regardless of the tumor’s anatomical origin.
Howard McLeod, Pharm.D., professor of medicine, of genetics and of molecular biology and pharmacology, is the study’s senior author.
“This study is the first time the pathway for a drug’s effect has been analyzed in tumors from different anatomical locations,” said McLeod, also director of the pharmacology core at the Siteman Cancer Center and a member of the National Institutes of Health Pharmacogenetics Research Network.
“We’ve shown that drug effect is independent of where the tumor came from in the body. If further studies confirm that a tumor-specific approach is better than the current anatomical emphasis, oncologists may have to stop thinking of themselves as colon cancer or breast cancer specialists and let the cancer tell them which drugs to use for each specific patient.”
The research team analyzed 255 samples of eight different cancers — colon, breast, prostate, ovary, lung, brain, melanoma and lymphoma — and measured the amounts of specific proteins known to influence the effect of irinotecan, a commonly used anticancer agent. The study will appear in an upcoming issue of the Journal of Pathology.
The protein levels that determine irinotecan’s effectiveness were found to be independent of the anatomical origin of the tumor. So, for instance, the colon tumors studied varied widely in the levels of these proteins. The same variation in protein levels held true for all the tumor types the researchers examined.
“This study provides evidence that the pharmacological pathway of a drug is important, with significant treatment implications,” said Rochelle M. Long, Ph.D., of the National Institute of General Medical Sciences and program director for the NIH Pharmacogenetics Research Network.
The researchers found that, independent of anatomical origin, some tumors had high amounts of irinotecan’s cellular target, a protein labeled TOP1, while other tumors had very little. Irinotecan would likely be ineffective in tumors with low TOP1 levels. They also found that tumors varied greatly in the amounts of proteins that transport irinotecan into and out of their cells and in the amounts of proteins that break down irinotecan. These variations determine how well irinotecan will work in a particular tumor.
“Because tumor response can’t be predicted from anatomical location, we should start selecting treatments based on what genes and proteins can tell us about how the tumor will respond to a drug,” McLeod said. “If we rely just on what has clinically been shown to work in some cases for a particular anatomically defined cancer, we may not initially choose the best therapy for the individual patient.
“And with advanced cancer, a patient may get only one shot at the right therapy; making the wrong choice could be deadly.”
Under current treatment selection methods, virtually no chemotherapeutic drug has been successful in more than 50 percent of patients with advanced cancer, according to McLeod. But instead of considering a drug that works only 10 percent of the time as a failure, he said it would be better to consider such a drug effective for one in 10 tumors and to search for the agents among the current arsenal of chemotherapeutic drugs that will work for the rest.
“We have more than 70 FDA-approved drugs that potentially could be useful for a particular tumor,” McLeod said. “We are now working on methods that can be used to identify those drugs that will work for each patient’s tumor.”
Having a good tumor-drug match not only would improve survival rates, but it would also be cost-effective, according to McLeod.
“Since modern cancer therapies can be expensive — sometimes approaching the cost of a bone marrow transplant — the high cost reinforces the necessity of choosing the right therapy the first time,” he said.